📊 PLSE Key Takeaways
Is Pulse Biosciences, Inc.. (PLSE) a Good Investment?
Pulse Biosciences is a pre-commercial or very early-stage medical device company with only $350K in revenue against $76.9M in operating losses, indicating it has not yet achieved meaningful commercialization. While the company maintains a strong cash position of $80.7M with zero debt and excellent liquidity, the accelerating losses (down 35.8% YoY), massive cash burn of $54.1M annually, and absence of revenue traction suggest execution risk and a runway of approximately 18-24 months at current burn rate. Without demonstrated product-market fit or credible near-term commercialization pathway, the company presents a highly speculative, high-risk fundamental profile.
Why Buy Pulse Biosciences, Inc.. Stock? PLSE Key Strengths
- Strong cash position of $80.7M with no debt, providing 18-24 month runway
- Excellent liquidity metrics (current ratio 10.53x, quick ratio 10.51x)
- Operates in medical device sector with potential for high-margin products at scale
- Minimal liabilities ($13.9M) relative to equity base
PLSE Stock Risks: Pulse Biosciences, Inc.. Investment Risks
- Pre-commercial or extremely early-stage revenue ($350K) with no evidence of business traction
- Massive operating losses ($76.9M) accelerating YoY (-35.8% net income deterioration)
- Negative operating cash flow of $54.1M annually indicates unsustainable burn rate
- No visibility to near-term profitability or clear path to revenue growth
- High execution risk typical of clinical-stage or development-stage medtech companies
- Cash depletion risk if commercialization is delayed or unsuccessful
Key Metrics to Watch
- Quarterly revenue growth and path to meaningful commercialization
- Operating cash burn rate and cash runway remaining
- Clinical trial progress, regulatory approvals, and product launch timelines
- Gross margin achievement once products reach meaningful scale
- Insider buying/selling patterns as indicator of management confidence
Pulse Biosciences, Inc.. (PLSE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.53x current ratio provides a solid financial cushion.
PLSE Profit Margin, ROE & Profitability Analysis
PLSE vs Healthcare Sector: How Pulse Biosciences, Inc.. Compares
How Pulse Biosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pulse Biosciences, Inc.. Stock Overvalued? PLSE Valuation Analysis 2026
Based on fundamental analysis, Pulse Biosciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pulse Biosciences, Inc.. Balance Sheet: PLSE Debt, Cash & Liquidity
PLSE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pulse Biosciences, Inc..'s revenue has declined by 75% over the 5-year period, indicating business contraction. The most recent EPS of $-0.92 indicates the company is currently unprofitable.
PLSE Revenue Growth, EPS Growth & YoY Performance
PLSE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$12.7M | $-0.21 |
| Q2 2025 | N/A | -$11.4M | $-0.20 |
| Q1 2025 | N/A | -$10.1M | $-0.18 |
| Q3 2024 | N/A | -$10.6M | $-0.19 |
| Q2 2024 | N/A | -$9.9M | $-0.20 |
| Q1 2024 | N/A | -$9.8M | $-0.18 |
| Q3 2023 | N/A | -$10.6M | $-0.19 |
| Q2 2023 | N/A | -$9.9M | $-0.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pulse Biosciences, Inc.. Dividends, Buybacks & Capital Allocation
PLSE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pulse Biosciences, Inc.. (CIK: 0001625101)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PLSE
What is the AI rating for PLSE?
Pulse Biosciences, Inc.. (PLSE) has an AI rating of STRONG SELL with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PLSE's key strengths?
Claude: Strong cash position of $80.7M with no debt, providing 18-24 month runway. Excellent liquidity metrics (current ratio 10.53x, quick ratio 10.51x).
What are the risks of investing in PLSE?
Claude: Pre-commercial or extremely early-stage revenue ($350K) with no evidence of business traction. Massive operating losses ($76.9M) accelerating YoY (-35.8% net income deterioration).
What is PLSE's revenue and growth?
Pulse Biosciences, Inc.. reported revenue of $350.0K.
Does PLSE pay dividends?
Pulse Biosciences, Inc.. does not currently pay dividends.
Where can I find PLSE SEC filings?
Official SEC filings for Pulse Biosciences, Inc.. (CIK: 0001625101) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PLSE's EPS?
Pulse Biosciences, Inc.. has a diluted EPS of $-1.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PLSE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pulse Biosciences, Inc.. has a STRONG SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PLSE stock overvalued or undervalued?
Valuation metrics for PLSE: ROE of -90.2% (sector avg: 15%), net margin of -20,794.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PLSE stock in 2026?
Our dual AI analysis gives Pulse Biosciences, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PLSE's free cash flow?
Pulse Biosciences, Inc..'s operating cash flow is $-54.1M, with capital expenditures of $315.0K. FCF margin is -15,553.4%.
How does PLSE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -20,794.6% (avg: 12%), ROE -90.2% (avg: 15%), current ratio 10.53 (avg: 2).